{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:29:52Z","timestamp":1791973792278,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:00:00Z","timestamp":1709424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:00:00Z","timestamp":1709424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Suzhou Health Talents Training Project","award":["GSWS2019002"],"award-info":[{"award-number":["GSWS2019002"]}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20200203"],"award-info":[{"award-number":["BK20200203"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Suzhou Health Talents Training Project","award":["GSWS2020022"],"award-info":[{"award-number":["GSWS2020022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00415-024-12247-x","type":"journal-article","created":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T15:01:31Z","timestamp":1709478091000},"page":"2298-2308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"271","author":[{"given":"Jiaxuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianchen","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruisi","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-0845","authenticated-orcid":false,"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,3]]},"reference":[{"key":"12247_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A et al (2019) Myasthenia gravis. Nat Rev Dis Primers 5:30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"issue":"143\u2013153","key":"12247_CR2","doi-asserted-by":"publisher","first-page":"20180129","DOI":"10.1111\/nyas.13592","volume":"1413","author":"A Vincent","year":"2018","unstructured":"Vincent A, Huda S, Cao M et al (2018) Serological and experimental studies in different forms of myasthenia gravis. Ann N Y Acad Sci 1413(143\u2013153):20180129. https:\/\/doi.org\/10.1111\/nyas.13592","journal-title":"Ann N Y Acad Sci"},{"key":"12247_CR3","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"key":"12247_CR4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41582-021-00547-z","volume":"17","author":"JD L\u00fcnemann","year":"2021","unstructured":"L\u00fcnemann JD (2021) Getting specific: targeting Fc receptors in myasthenia gravis. Nat Rev Neurol 17:597\u2013598. https:\/\/doi.org\/10.1038\/s41582-021-00547-z","journal-title":"Nat Rev Neurol"},{"key":"12247_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","volume":"36","author":"MK Hehir","year":"2018","unstructured":"Hehir MK, Silvestri NJ (2018) Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology. Neurol Clin 36:253\u2013260. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.002","journal-title":"Neurol Clin"},{"key":"12247_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO et al (2010) A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol 10:46. https:\/\/doi.org\/10.1186\/1471-2377-10-46","journal-title":"BMC Neurol"},{"issue":"25\u201345","key":"12247_CR7","doi-asserted-by":"publisher","first-page":"20230404","DOI":"10.2147\/itt.S377056","volume":"12","author":"SS Nair","year":"2023","unstructured":"Nair SS, Jacob S (2023) Novel immunotherapies for myasthenia gravis. Immunotargets Ther 12(25\u201345):20230404. https:\/\/doi.org\/10.2147\/itt.S377056","journal-title":"Immunotargets Ther"},{"issue":"151\u2013160","key":"12247_CR8","doi-asserted-by":"publisher","first-page":"20110322","DOI":"10.2147\/ndt.S8915","volume":"7","author":"R Mantegazza","year":"2011","unstructured":"Mantegazza R, Bonanno S, Camera G et al (2011) Current and emerging therapies for the treatment of myasthenia gravis. Neuropsychiatr Dis Treat 7(151\u2013160):20110322. https:\/\/doi.org\/10.2147\/ndt.S8915","journal-title":"Neuropsychiatr Dis Treat"},{"key":"12247_CR9","doi-asserted-by":"publisher","first-page":"20180118","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C (2018) When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 11:20180118. https:\/\/doi.org\/10.1177\/1756285617749134","journal-title":"Ther Adv Neurol Disord"},{"issue":"114\u2013122","key":"12247_CR10","doi-asserted-by":"publisher","first-page":"20201103","DOI":"10.1212\/wnl.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96(114\u2013122):20201103. https:\/\/doi.org\/10.1212\/wnl.0000000000011124","journal-title":"Neurology"},{"issue":"175628641983224","key":"12247_CR11","doi-asserted-by":"publisher","first-page":"20190301","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N et al (2019) Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord 12(1756286419832242):20190301. https:\/\/doi.org\/10.1177\/1756286419832242","journal-title":"Ther Adv Neurol Disord"},{"issue":"538","key":"12247_CR12","doi-asserted-by":"publisher","first-page":"20200630","DOI":"10.3389\/fneur.2020.00538","volume":"11","author":"D Menon","year":"2020","unstructured":"Menon D, Barnett C, Bril V (2020) Novel treatments in myasthenia gravis. Front Neurol 11(538):20200630. https:\/\/doi.org\/10.3389\/fneur.2020.00538","journal-title":"Front Neurol"},{"key":"12247_CR13","doi-asserted-by":"publisher","first-page":"20211221","DOI":"10.1177\/17562864211065406","volume":"14","author":"C Schneider-Gold","year":"2021","unstructured":"Schneider-Gold C, Gilhus NE (2021) Advances and challenges in the treatment of myasthenia gravis. Ther Adv Neurol Disord 14:20211221. https:\/\/doi.org\/10.1177\/17562864211065406","journal-title":"Ther Adv Neurol Disord"},{"key":"12247_CR14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1474-4422(21)00357-4","volume":"21","author":"MG Huijbers","year":"2022","unstructured":"Huijbers MG, Marx A, Plomp JJ et al (2022) Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol 21:163\u2013175. https:\/\/doi.org\/10.1016\/S1474-4422(21)00357-4","journal-title":"Lancet Neurol"},{"key":"12247_CR15","doi-asserted-by":"publisher","first-page":"20130501","DOI":"10.1101\/cshperspect.a009167","volume":"5","author":"SJ Burden","year":"2013","unstructured":"Burden SJ, Yumoto N, Zhang W (2013) The role of MuSK in synapse formation and neuromuscular disease. Cold Spring Harb Perspect Biol 5:20130501. https:\/\/doi.org\/10.1101\/cshperspect.a009167","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"12247_CR16","doi-asserted-by":"publisher","first-page":"20210528","DOI":"10.3390\/ijms22115755","volume":"22","author":"CW Keller","year":"2021","unstructured":"Keller CW, Pawlitzki M, Wiendl H et al (2021) Fc-receptor targeted therapies for the treatment of myasthenia gravis. Int J Mol Sci 22:20210528. https:\/\/doi.org\/10.3390\/ijms22115755","journal-title":"Int J Mol Sci"},{"key":"12247_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/B978-0-12-820472-6.00046-3","volume-title":"Comprehensive pharmacology","author":"NE Gilhus","year":"2022","unstructured":"Gilhus NE, Lindroos J (2022) 5.25\u2014Myasthenia gravis. In: Kenakin T (ed) Comprehensive pharmacology. Elsevier, Oxford, pp 461\u2013478"},{"key":"12247_CR18","doi-asserted-by":"publisher","first-page":"20783","DOI":"10.1073\/pnas.1313944110","volume":"110","author":"MG Huijbers","year":"2013","unstructured":"Huijbers MG, Zhang W, Klooster R et al (2013) MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci 110:20783\u201320788","journal-title":"Proc Natl Acad Sci"},{"key":"12247_CR19","doi-asserted-by":"publisher","first-page":"20210226","DOI":"10.1177\/1756286421997381","volume":"14","author":"MC Dalakas","year":"2021","unstructured":"Dalakas MC, Spaeth PJ (2021) The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord 14:20210226. https:\/\/doi.org\/10.1177\/1756286421997381","journal-title":"Ther Adv Neurol Disord"},{"key":"12247_CR20","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed) 339:2700. https:\/\/doi.org\/10.1136\/bmj.b2700. (2009\/07\/23)","journal-title":"BMJ (Clinical research ed)"},{"key":"12247_CR21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/jrsm.38","volume":"2","author":"JJ Shuster","year":"2011","unstructured":"Shuster JJ (2011) Review: cochrane handbook for systematic reviews for interventions, Version 5.1.0, published 3\/2011. Julian P.T. Higgins and Sally Green, Eitors. Res Synthesis Methods 2:126\u2013130. https:\/\/doi.org\/10.1002\/jrsm.38","journal-title":"Res Synthesis Methods"},{"key":"12247_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA (2022) Efgartigimod: first approval. Drugs 82:341\u2013348. https:\/\/doi.org\/10.1007\/s40265-022-01678-3","journal-title":"Drugs"},{"key":"12247_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01933-1","author":"SM Hoy","year":"2023","unstructured":"Hoy SM (2023) Rozanolixizumab: first approval. Drugs. https:\/\/doi.org\/10.1007\/s40265-023-01933-1","journal-title":"Drugs"},{"key":"12247_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15872","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Pane C, Espinosa PE et al (2023) Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.15872","journal-title":"Eur J Neurol"},{"issue":"553\u2013563","key":"12247_CR25","doi-asserted-by":"publisher","first-page":"20230404","DOI":"10.2217\/imt-2022-0298","volume":"15","author":"A Sivadasan","year":"2023","unstructured":"Sivadasan A, Bril V (2023) Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis. Immunotherapy 15(553\u2013563):20230404. https:\/\/doi.org\/10.2217\/imt-2022-0298","journal-title":"Immunotherapy"},{"key":"12247_CR26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, Bril V, Vu T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526\u2013536. https:\/\/doi.org\/10.1016\/S1474-4422(21)00159-9","journal-title":"Lancet Neurol"},{"key":"12247_CR27","unstructured":"argenx. Vyvgart\u2122 (efgartigimod alfa-fcab) injection, for intravenous use: US highlights of prescribing information. 2021. https:\/\/argenx.com\/product\/vyvgart-prescribing-information.pdf"},{"key":"12247_CR28","unstructured":"https:\/\/www.businesswire.com\/news\/home\/20220321005941\/en\/argenx-Announces-Positive-Topline-Phase-3-Data-From-ADAPT-SC-Study-Evaluating-Subcutaneous-Efgartigimod-for-Generalized-Myasthenia-Gravis aAPTPDFA-SSESEfGMGIcA."},{"issue":"1111\u20131130","key":"12247_CR29","doi-asserted-by":"publisher","first-page":"20180912","DOI":"10.1080\/19420862.2018.1505464","volume":"10","author":"B Smith","year":"2018","unstructured":"Smith B, Kiessling A, Lledo-Garcia R et al (2018) Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs 10(1111\u20131130):20180912. https:\/\/doi.org\/10.1080\/19420862.2018.1505464","journal-title":"MAbs"},{"key":"12247_CR30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J et al (2023) Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 22:383\u2013394. https:\/\/doi.org\/10.1016\/S1474-4422(23)00077-7","journal-title":"Lancet Neurol"},{"key":"12247_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan1208","volume":"9","author":"P Kiessling","year":"2017","unstructured":"Kiessling P, Lledo-Garcia R, Watanabe S et al (2017) The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Transl Med 9:eaan1208. https:\/\/doi.org\/10.1126\/scitranslmed.aan1208","journal-title":"Sci Transl Med"},{"issue":"1769\u20131779","key":"12247_CR32","doi-asserted-by":"publisher","first-page":"20210716","DOI":"10.1111\/cts.13019","volume":"14","author":"DYH Yap","year":"2021","unstructured":"Yap DYH, Hai J, Lee PCH et al (2021) Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers. Clin Transl Sci 14(1769\u20131779):20210716. https:\/\/doi.org\/10.1111\/cts.13019","journal-title":"Clin Transl Sci"},{"key":"12247_CR33","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.4103\/1673-5374.363824","volume":"18","author":"LN Zhu","year":"2023","unstructured":"Zhu LN, Hou HM, Wang S et al (2023) FcRn inhibitors: a novel option for the treatment of myasthenia gravis. Neural Regen Res 18:1637\u20131644. https:\/\/doi.org\/10.4103\/1673-5374.363824","journal-title":"Neural Regen Res"},{"issue":"815\u2013834","key":"12247_CR34","doi-asserted-by":"publisher","first-page":"20220412","DOI":"10.1007\/s40120-022-00345-9","volume":"11","author":"C Yan","year":"2022","unstructured":"Yan C, Duan RS, Yang H et al (2022) Therapeutic effects of batoclimab in Chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study. Neurol Ther 11(815\u2013834):20220412. https:\/\/doi.org\/10.1007\/s40120-022-00345-9","journal-title":"Neurol Ther"},{"key":"12247_CR35","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1212\/01.wnl.0000903328.46907.49","volume":"99","author":"S Ramchandren","year":"2022","unstructured":"Ramchandren S, Sanga P, Burcklen M et al (2022) Vivacity MG PHASE 3 STUdy: clinical trial of nipocalimab administered to adults with generalized myasthenia gravis. Neurology 99:S41\u2013S41. https:\/\/doi.org\/10.1212\/01.wnl.0000903328.46907.49","journal-title":"Neurology"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12247-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12247-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12247-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T07:19:28Z","timestamp":1714202368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12247-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,3]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["12247"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12247-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,3]]},"assertion":[{"value":"3 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}